Achromatopsia

Meet the 2019 Co-chairs for Young Leaders

September 28th, 2018 by FFB Canada

Launched in 2015 by the Foundation Fighting Blindness, the National Young Leaders Program saw a lot of growth in 2018. Designed to provide Canadian youth living with vision loss and blindness with mentorship and career-building opportunities, the Program is oriented around an in-person Summit—you can read more about this year’s Summit HERE—and is set to…

Read More

Announcing the FFB’s Vision Care Pathways

September 27th, 2018 by FFB Canada

Along with the brain, the eye is one of the human body’s most intricate components, an elaborate collection of parts working in tandem to do one thing: gather external light and focus it on a small area of tissue at the back of the eye. Cells housed in the tissue absorb light particles and transmit…

Read More

RNA Therapies for Inherited Retinal Diseases (IRDs)

May 1st, 2018 by Dr. Mary Sunderland

I recently participated in a tremendously inspiring meeting, hosted by ProQR, which is a company that is creating new treatments for people living with rare diseases, including blinding eye diseases. ProQR specializes in developing RNA therapeutics, and I was there to learn about a new clinical trial that they are planning to treat the inherited…

Read More

Everything You Need to Know About FFB Canada’s Patient Registry

February 6th, 2018 by FFB Canada

Fill out the online form on our Patient Registry page to learn more about how you can enroll. Click here to download a printable version of this article/fact sheet: PDF/Word. The Patient Registry is a secure medical database that was designed to connect people living with inherited retinal diseases (IRDs) to clinical trials, to improve…

Read More

Four Vision Research and Treatment Trends to Watch in 2018   

January 22nd, 2018 by FFB Canada

With the December 2017 announcement that the world’s first ocular gene therapy had received approval by the U. S. Food and Drug Administration (FDA), there’s no doubt that 2017 was a landmark year for gene therapy. Looking back, 2017 was a year of firsts, including the first stem cell therapy clinical trial for macular degeneration…

Read More

2017 in Review: The Most-Read FFB Stories of 2017

December 22nd, 2017 by FFB Canada

At the FFB, we love writing about vision research. In 2017, we wrote more than 50 stories to share news about stem cell discoveries, CRISPR gene-editing, promising new drug therapies, and emerging treatments for blinding eye disease. Have you read them all? The best place to start is with our top 10 most-read stories of…

Read More

First gene therapy for a blinding eye disease receives FDA approval

December 19th, 2017 by Dr. Mary Sunderland

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the US that targets a disease caused by mutations in a specific gene. The next steps involve determining the price for Luxturna, which poses…

Read More